



# BEYOND CELIAC: CATALYST FOR A CURE BY 2030

## OUR SCIENTIFIC STRATEGY

A cure to Beyond Celiac means real treatment options so those with celiac disease can eat without fear.

**20%** OF KIDS WITH CELIAC DISEASE are not healing on the gluten-free diet.



Celiac disease is associated with a higher risk of brain damage and mental health issues.

Celiac disease can lead to anemia, infertility, malnutrition, osteoporosis, and even certain cancers



**44%** ON THE GLUTEN-FREE DIET

still get "glutened" once a month.

## SCIENTIFIC PRIORITIES

### EVIDENCE GENERATION



**Highlighting the seriousness of celiac disease**

By collecting and analyzing robust data on the burden of celiac disease, we can increase awareness and make a compelling case for additional investments from government agencies, pharmaceutical companies, biotech and more.

**Accelerate scientific progress toward a cure**

Making investments in promising new research that translates quickly from scientific investigation to clinical use can expedite development of treatments for patients.

### TRANSLATIONAL RESEARCH



### CLINICAL TRIALS



**Enabling faster approval of treatments**

As the nation's top recruiter for celiac disease clinical trials, we will continue educating the community about the importance of participating in trials and working with pharmaceutical companies to ensure trials are designed with patient perspectives in mind.

**Accelerating progress with venture philanthropy**

We will invest significant resources to identify and accelerate progress of promising treatments utilizing our networks of financial, scientific, and regulatory partners, and our position as the leading patient advocate and trial enroller in CD.

### BEYOND CELIAC INVESTMENTS

## PLAN ENABLERS



Our **diversified funding** strategy pools resources from multiple venues to invest in opportunities with the highest potential assets and increases the overall level of capital supporting celiac disease research.



We embrace and leverage **strategic partnerships** and strong collaborations to advance our plan priorities, overcome challenges and maximize progress toward a cure.



Our **targeted advocacy** efforts amplify the patient voice, soliciting investment of public funds into research/policies supporting the development and equitable access to effective treatments.



## OUR SCIENCE TEAM

**DEBRA SILBERG, MD, PHD, FAGG**

Chief Scientific Officer



**KATE AVERY, MPH**

Director of Research and Patient Engagement



**ERIN MILLER, MPH**

Associate Science Project Manager



**AMY RATNER**

Director of Scientific Affairs

AND THE BEYOND CELIAC SCIENTIFIC ADVISORY BOARD



Learn more at [beyondceliac.org/scienceplan](https://beyondceliac.org/scienceplan)